Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-02-21

AUTHORS

Rana Maroun, Laura Mitrofan, Laure Benjamin, Gaelle Nachbaur, Franck Maunoury, Philippe Le Jeunne, Isabelle Durand-Zaleski

ABSTRACT

BackgroundPatient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real world setting.MethodsA retrospective analysis was performed using IQVIA real world oncology cross-sectional survey data, a retrospective treatment database collecting anonymized patient-level data in Europe. Data on treatment naïve patients with mRCC who received a first-line targeted therapy in France were extracted for the period 2005–2015. Descriptive analyses were performed on treatment patterns, patient characteristics and safety profiles. Progression Free Survival (PFS) was determined using Kaplan-Meier survival analysis.ResultsOne thousand three hundred thirty-one patients with mRCC who received a first-line targeted therapy were included. The male/female sex ratio was 2.5 and 66% of patients were aged > 60 years. 83% of patients had clear cell adenocarcinoma. 83% of patients underwent a surgical procedure, 10% had radiotherapy. In patients who received a first-line targeted therapy, 73% received sunitinib. The mean time from diagnosis to first-line treatment by targeted therapies in patients initially diagnosed with metastatic disease was 3.3 months [95% CI:2.5–4.1]. In patients who received second-line targeted therapy n = 257 (19%), the most frequently observed treatment sequences were sunitinib-everolimus (33%) and sunitinib-sorafenib (27%). Adverse events data were available for 501 patients and adverse events were documented in 70% of patients, most frequently diarrhoea. The overall median PFS was 13 months [95% CI:11.5–16].ConclusionPatient characteristics were consistent with the literature. Treatment patterns appeared to follow current practice guidelines. Despite some variations, PFS in our study seems to be consistent with findings from other real world studies. Nevertheless, PFS results were higher than those observed in clinical trials. Due to the use of cross-sectional data, PFS in our study should be interpreted with caution. More... »

PAGES

214

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-018-4117-z

DOI

http://dx.doi.org/10.1186/s12885-018-4117-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101139210

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29466966


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Management", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Care Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment, Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Patterns, Physicians'", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Public Health Surveillance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "INSERM, ECEVE, UMR 1123, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "GlaxoSmithKline, Health Economics and Outcomes Research, Rueil Malmaison, France", 
            "INSERM, ECEVE, UMR 1123, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maroun", 
        "givenName": "Rana", 
        "id": "sg:person.01150453413.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150453413.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, La D\u00e9fense, France", 
          "id": "http://www.grid.ac/institutes/grid.434277.1", 
          "name": [
            "IQVIA, La D\u00e9fense, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mitrofan", 
        "givenName": "Laura", 
        "id": "sg:person.014723125413.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014723125413.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline, Health Economics and Outcomes Research, Rueil Malmaison, France", 
          "id": "http://www.grid.ac/institutes/grid.476503.3", 
          "name": [
            "GlaxoSmithKline, Health Economics and Outcomes Research, Rueil Malmaison, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Benjamin", 
        "givenName": "Laure", 
        "id": "sg:person.0777101415.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777101415.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline, Health Economics and Outcomes Research, Rueil Malmaison, France", 
          "id": "http://www.grid.ac/institutes/grid.476503.3", 
          "name": [
            "GlaxoSmithKline, Health Economics and Outcomes Research, Rueil Malmaison, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nachbaur", 
        "givenName": "Gaelle", 
        "id": "sg:person.01075536373.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075536373.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Statesia, Le Mans, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Statesia, Le Mans, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maunoury", 
        "givenName": "Franck", 
        "id": "sg:person.01000241105.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000241105.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, La D\u00e9fense, France", 
          "id": "http://www.grid.ac/institutes/grid.434277.1", 
          "name": [
            "IQVIA, La D\u00e9fense, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Jeunne", 
        "givenName": "Philippe", 
        "id": "sg:person.01022440723.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022440723.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "URC-ECO, APHP, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.50550.35", 
          "name": [
            "INSERM, ECEVE, UMR 1123, Paris, France", 
            "URC-ECO, APHP, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "Isabelle", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-02-21", 
    "datePublishedReg": "2018-02-21", 
    "description": "BackgroundPatient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real world setting.MethodsA retrospective analysis was performed using IQVIA real world oncology cross-sectional survey data, a retrospective treatment database collecting anonymized patient-level data in Europe. Data on treatment na\u00efve patients with mRCC who received a first-line targeted therapy in France were extracted for the period 2005\u20132015. Descriptive analyses were performed on treatment patterns, patient characteristics and safety profiles. Progression Free Survival (PFS) was determined using Kaplan-Meier survival analysis.ResultsOne thousand three hundred thirty-one patients with mRCC who received a first-line targeted therapy were included. The male/female sex ratio was 2.5 and 66% of patients were aged >\u200960\u00a0years. 83% of patients had clear cell adenocarcinoma. 83% of patients underwent a surgical procedure, 10% had radiotherapy. In patients who received a first-line targeted therapy, 73% received sunitinib. The mean time from diagnosis to first-line treatment by targeted therapies in patients initially diagnosed with metastatic disease was 3.3\u00a0months [95% CI:2.5\u20134.1]. In patients who received second-line targeted therapy n\u2009=\u2009257 (19%), the most frequently observed treatment sequences were sunitinib-everolimus (33%) and sunitinib-sorafenib (27%). Adverse events data were available for 501 patients and adverse events were documented in 70% of patients, most frequently diarrhoea. The overall median PFS was 13\u00a0months [95% CI:11.5\u201316].ConclusionPatient characteristics were consistent with the literature. Treatment patterns appeared to follow current practice guidelines. Despite some variations, PFS in our study seems to be consistent with findings from other real world studies. Nevertheless, PFS results were higher than those observed in clinical trials. Due to the use of cross-sectional data, PFS in our study should be interpreted with caution.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-018-4117-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "progression-free survival", 
      "free survival", 
      "treatment patterns", 
      "retrospective analysis", 
      "overall median progression-free survival", 
      "metastatic renal cell carcinoma patients", 
      "median progression-free survival", 
      "renal cell carcinoma patients", 
      "real-life clinical practice", 
      "Kaplan-Meier survival analysis", 
      "treatment-na\u00efve patients", 
      "cross-sectional data", 
      "first-line treatment", 
      "clear cell adenocarcinoma", 
      "cell carcinoma patients", 
      "current practice guidelines", 
      "adverse event data", 
      "renal cell carcinoma", 
      "patient-level data", 
      "real-world study", 
      "sunitinib-everolimus", 
      "ConclusionPatient characteristics", 
      "na\u00efve patients", 
      "patient characteristics", 
      "metastatic disease", 
      "adverse events", 
      "carcinoma patients", 
      "randomized trials", 
      "survival outcomes", 
      "safety profile", 
      "cell carcinoma", 
      "cell adenocarcinoma", 
      "PFS results", 
      "clinical trials", 
      "treatment pathways", 
      "practice guidelines", 
      "drug costs", 
      "surgical procedures", 
      "patients", 
      "clinical practice", 
      "female sex ratio", 
      "real-life patterns", 
      "real-world setting", 
      "treatment database", 
      "survival analysis", 
      "therapy", 
      "treatment sequence", 
      "mean time", 
      "cross-sectional survey data", 
      "survival", 
      "trials", 
      "months", 
      "world studies", 
      "descriptive analysis", 
      "world settings", 
      "sunitinib", 
      "adenocarcinoma", 
      "carcinoma", 
      "radiotherapy", 
      "disease", 
      "study", 
      "diagnosis", 
      "care", 
      "outcomes", 
      "treatment", 
      "life patterns", 
      "safety", 
      "guidelines", 
      "sex ratio", 
      "thirties", 
      "data", 
      "caution", 
      "patterns", 
      "years", 
      "pathway", 
      "findings", 
      "setting", 
      "analysis", 
      "database", 
      "event data", 
      "events", 
      "characteristics", 
      "procedure", 
      "profile", 
      "objective", 
      "survey data", 
      "use", 
      "practice", 
      "literature", 
      "ratio", 
      "time", 
      "results", 
      "France", 
      "Europe", 
      "cost", 
      "sequence", 
      "variation"
    ], 
    "name": "Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data", 
    "pagination": "214", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101139210"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-018-4117-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29466966"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-018-4117-z", 
      "https://app.dimensions.ai/details/publication/pub.1101139210"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_780.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-018-4117-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4117-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4117-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4117-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4117-z'


 

This table displays all metadata directly associated to this object as RDF triples.

274 TRIPLES      20 PREDICATES      138 URIs      130 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-018-4117-z schema:about N21d796dde8e546d79f5e17860d8573d7
2 N2cec5c27fc254d7c9c0ce22d837ca2f4
3 N2e85112fd217472c8fc2a7215f899f14
4 N2f50807b216b43d9b7713edb1a34477c
5 N4d3e6e975efa4a0e8af1cb8ac9a2c938
6 N572b7029ca9447e996de94f51aeb9515
7 N58c21fcec5534f439388348d63513b5e
8 N5a87b346aef3472d88423398dccf4e49
9 N8de34f8ea7a044b58e0c7c45723038c8
10 N9821592d7b9049d7a7d87ee048227294
11 Nb7813d559de3495b95627a006a68dff3
12 Nc6151cc63aaa4f98a1f803b6e6430e47
13 Nd38305c04658498ebd48c78f2c8f2b32
14 Nec62a165b45b486f879bd4e640c0d3c2
15 Nf4d7b0653bfa421db17614fa66648ece
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N7e06352ffde347ffb05b877b59842c7e
19 schema:datePublished 2018-02-21
20 schema:datePublishedReg 2018-02-21
21 schema:description BackgroundPatient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real world setting.MethodsA retrospective analysis was performed using IQVIA real world oncology cross-sectional survey data, a retrospective treatment database collecting anonymized patient-level data in Europe. Data on treatment naïve patients with mRCC who received a first-line targeted therapy in France were extracted for the period 2005–2015. Descriptive analyses were performed on treatment patterns, patient characteristics and safety profiles. Progression Free Survival (PFS) was determined using Kaplan-Meier survival analysis.ResultsOne thousand three hundred thirty-one patients with mRCC who received a first-line targeted therapy were included. The male/female sex ratio was 2.5 and 66% of patients were aged > 60 years. 83% of patients had clear cell adenocarcinoma. 83% of patients underwent a surgical procedure, 10% had radiotherapy. In patients who received a first-line targeted therapy, 73% received sunitinib. The mean time from diagnosis to first-line treatment by targeted therapies in patients initially diagnosed with metastatic disease was 3.3 months [95% CI:2.5–4.1]. In patients who received second-line targeted therapy n = 257 (19%), the most frequently observed treatment sequences were sunitinib-everolimus (33%) and sunitinib-sorafenib (27%). Adverse events data were available for 501 patients and adverse events were documented in 70% of patients, most frequently diarrhoea. The overall median PFS was 13 months [95% CI:11.5–16].ConclusionPatient characteristics were consistent with the literature. Treatment patterns appeared to follow current practice guidelines. Despite some variations, PFS in our study seems to be consistent with findings from other real world studies. Nevertheless, PFS results were higher than those observed in clinical trials. Due to the use of cross-sectional data, PFS in our study should be interpreted with caution.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N91557b39fe9241479d0c1828c81ed7f6
25 Nf7feab4dabe64257bb18b1dc644e0bea
26 sg:journal.1024632
27 schema:keywords ConclusionPatient characteristics
28 Europe
29 France
30 Kaplan-Meier survival analysis
31 PFS results
32 adenocarcinoma
33 adverse event data
34 adverse events
35 analysis
36 carcinoma
37 carcinoma patients
38 care
39 caution
40 cell adenocarcinoma
41 cell carcinoma
42 cell carcinoma patients
43 characteristics
44 clear cell adenocarcinoma
45 clinical practice
46 clinical trials
47 cost
48 cross-sectional data
49 cross-sectional survey data
50 current practice guidelines
51 data
52 database
53 descriptive analysis
54 diagnosis
55 disease
56 drug costs
57 event data
58 events
59 female sex ratio
60 findings
61 first-line treatment
62 free survival
63 guidelines
64 life patterns
65 literature
66 mean time
67 median progression-free survival
68 metastatic disease
69 metastatic renal cell carcinoma
70 metastatic renal cell carcinoma patients
71 months
72 naïve patients
73 objective
74 outcomes
75 overall median progression-free survival
76 pathway
77 patient characteristics
78 patient-level data
79 patients
80 patterns
81 practice
82 practice guidelines
83 procedure
84 profile
85 progression-free survival
86 radiotherapy
87 randomized trials
88 ratio
89 real-life clinical practice
90 real-life patterns
91 real-world setting
92 real-world study
93 renal cell carcinoma
94 renal cell carcinoma patients
95 results
96 retrospective analysis
97 safety
98 safety profile
99 sequence
100 setting
101 sex ratio
102 study
103 sunitinib
104 sunitinib-everolimus
105 surgical procedures
106 survey data
107 survival
108 survival analysis
109 survival outcomes
110 therapy
111 thirties
112 time
113 treatment
114 treatment database
115 treatment pathways
116 treatment patterns
117 treatment sequence
118 treatment-naïve patients
119 trials
120 use
121 variation
122 world settings
123 world studies
124 years
125 schema:name Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data
126 schema:pagination 214
127 schema:productId N22845b713f83400e9eda69b23b2dd5b4
128 Nb8018ce24b85441ba1f8a09917228703
129 Nc274d2b3f3e44087ac3feabc71cdd178
130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101139210
131 https://doi.org/10.1186/s12885-018-4117-z
132 schema:sdDatePublished 2022-10-01T06:44
133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
134 schema:sdPublisher Nebf40033adbc409a94c2a3fa2b1a516e
135 schema:url https://doi.org/10.1186/s12885-018-4117-z
136 sgo:license sg:explorer/license/
137 sgo:sdDataset articles
138 rdf:type schema:ScholarlyArticle
139 N044c6043c4f8401cbad481cec3626822 rdf:first sg:person.01327533357.46
140 rdf:rest rdf:nil
141 N21d796dde8e546d79f5e17860d8573d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 N22845b713f83400e9eda69b23b2dd5b4 schema:name doi
145 schema:value 10.1186/s12885-018-4117-z
146 rdf:type schema:PropertyValue
147 N2cec5c27fc254d7c9c0ce22d837ca2f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Practice Patterns, Physicians'
149 rdf:type schema:DefinedTerm
150 N2e85112fd217472c8fc2a7215f899f14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Combined Modality Therapy
152 rdf:type schema:DefinedTerm
153 N2f50807b216b43d9b7713edb1a34477c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Female
155 rdf:type schema:DefinedTerm
156 N4d3e6e975efa4a0e8af1cb8ac9a2c938 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Kidney Neoplasms
158 rdf:type schema:DefinedTerm
159 N572b7029ca9447e996de94f51aeb9515 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Health Care Costs
161 rdf:type schema:DefinedTerm
162 N58c21fcec5534f439388348d63513b5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Male
164 rdf:type schema:DefinedTerm
165 N5a87b346aef3472d88423398dccf4e49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Retrospective Studies
167 rdf:type schema:DefinedTerm
168 N5f931e4a19e643ddaef053e93592116e rdf:first sg:person.01000241105.76
169 rdf:rest N74d96f9910244f71bfc811f1206d0346
170 N6c798a7000ca4e0d8f3927ccc82c8a4f rdf:first sg:person.014723125413.03
171 rdf:rest Nbb7a1cbd92b0490aab087b6decfdde02
172 N74d96f9910244f71bfc811f1206d0346 rdf:first sg:person.01022440723.34
173 rdf:rest N044c6043c4f8401cbad481cec3626822
174 N7e06352ffde347ffb05b877b59842c7e rdf:first sg:person.01150453413.45
175 rdf:rest N6c798a7000ca4e0d8f3927ccc82c8a4f
176 N8de34f8ea7a044b58e0c7c45723038c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Carcinoma, Renal Cell
178 rdf:type schema:DefinedTerm
179 N91557b39fe9241479d0c1828c81ed7f6 schema:volumeNumber 18
180 rdf:type schema:PublicationVolume
181 N9821592d7b9049d7a7d87ee048227294 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Kaplan-Meier Estimate
183 rdf:type schema:DefinedTerm
184 Nb7813d559de3495b95627a006a68dff3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Disease Management
186 rdf:type schema:DefinedTerm
187 Nb8018ce24b85441ba1f8a09917228703 schema:name dimensions_id
188 schema:value pub.1101139210
189 rdf:type schema:PropertyValue
190 Nbb7a1cbd92b0490aab087b6decfdde02 rdf:first sg:person.0777101415.36
191 rdf:rest Nf9e6194e67a7456aa47c18cedd02a1c0
192 Nc274d2b3f3e44087ac3feabc71cdd178 schema:name pubmed_id
193 schema:value 29466966
194 rdf:type schema:PropertyValue
195 Nc6151cc63aaa4f98a1f803b6e6430e47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Public Health Surveillance
197 rdf:type schema:DefinedTerm
198 Nd38305c04658498ebd48c78f2c8f2b32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Outcome Assessment, Health Care
200 rdf:type schema:DefinedTerm
201 Nebf40033adbc409a94c2a3fa2b1a516e schema:name Springer Nature - SN SciGraph project
202 rdf:type schema:Organization
203 Nec62a165b45b486f879bd4e640c0d3c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Disease-Free Survival
205 rdf:type schema:DefinedTerm
206 Nf4d7b0653bfa421db17614fa66648ece schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Cross-Sectional Studies
208 rdf:type schema:DefinedTerm
209 Nf7feab4dabe64257bb18b1dc644e0bea schema:issueNumber 1
210 rdf:type schema:PublicationIssue
211 Nf9e6194e67a7456aa47c18cedd02a1c0 rdf:first sg:person.01075536373.44
212 rdf:rest N5f931e4a19e643ddaef053e93592116e
213 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
214 schema:name Medical and Health Sciences
215 rdf:type schema:DefinedTerm
216 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
217 schema:name Oncology and Carcinogenesis
218 rdf:type schema:DefinedTerm
219 sg:journal.1024632 schema:issn 1471-2407
220 schema:name BMC Cancer
221 schema:publisher Springer Nature
222 rdf:type schema:Periodical
223 sg:person.01000241105.76 schema:affiliation grid-institutes:None
224 schema:familyName Maunoury
225 schema:givenName Franck
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000241105.76
227 rdf:type schema:Person
228 sg:person.01022440723.34 schema:affiliation grid-institutes:grid.434277.1
229 schema:familyName Le Jeunne
230 schema:givenName Philippe
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022440723.34
232 rdf:type schema:Person
233 sg:person.01075536373.44 schema:affiliation grid-institutes:grid.476503.3
234 schema:familyName Nachbaur
235 schema:givenName Gaelle
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075536373.44
237 rdf:type schema:Person
238 sg:person.01150453413.45 schema:affiliation grid-institutes:grid.7429.8
239 schema:familyName Maroun
240 schema:givenName Rana
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150453413.45
242 rdf:type schema:Person
243 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.50550.35
244 schema:familyName Durand-Zaleski
245 schema:givenName Isabelle
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
247 rdf:type schema:Person
248 sg:person.014723125413.03 schema:affiliation grid-institutes:grid.434277.1
249 schema:familyName Mitrofan
250 schema:givenName Laura
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014723125413.03
252 rdf:type schema:Person
253 sg:person.0777101415.36 schema:affiliation grid-institutes:grid.476503.3
254 schema:familyName Benjamin
255 schema:givenName Laure
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0777101415.36
257 rdf:type schema:Person
258 grid-institutes:None schema:alternateName Statesia, Le Mans, France
259 schema:name Statesia, Le Mans, France
260 rdf:type schema:Organization
261 grid-institutes:grid.434277.1 schema:alternateName IQVIA, La Défense, France
262 schema:name IQVIA, La Défense, France
263 rdf:type schema:Organization
264 grid-institutes:grid.476503.3 schema:alternateName GlaxoSmithKline, Health Economics and Outcomes Research, Rueil Malmaison, France
265 schema:name GlaxoSmithKline, Health Economics and Outcomes Research, Rueil Malmaison, France
266 rdf:type schema:Organization
267 grid-institutes:grid.50550.35 schema:alternateName URC-ECO, APHP, Paris, France
268 schema:name INSERM, ECEVE, UMR 1123, Paris, France
269 URC-ECO, APHP, Paris, France
270 rdf:type schema:Organization
271 grid-institutes:grid.7429.8 schema:alternateName INSERM, ECEVE, UMR 1123, Paris, France
272 schema:name GlaxoSmithKline, Health Economics and Outcomes Research, Rueil Malmaison, France
273 INSERM, ECEVE, UMR 1123, Paris, France
274 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...